Maravai LifeSciences Holdings, Inc.

Informe acción NasdaqGS:MRVI

Capitalización de mercado: US$2.7b

Dividendos de Maravai LifeSciences Holdings

Dividendo controles de criterios 0/6

Maravai LifeSciences Holdings no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria0.3%
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Beneficios por acción-US$0.99
Rentabilidad por dividendo prevista a 3 años0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

May 14
Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Apr 07
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Feb 28
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Dec 19
Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Aug 14
Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Feb 28
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 01
Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Maravai Lifesciences temporarily reinstates Carl Hull as CEO

Oct 19

Maravai LifeSciences appoints former Danaher executive as CEO

Oct 03

Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M

Aug 04

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jun 27
Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 29
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Maravai Faces Skeptical Investors As Pandemic Enters New Period

Jan 27

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Dec 02
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

Oct 07
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Worth US$41.7 Based On Its Intrinsic Value?

Jul 01
Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Worth US$41.7 Based On Its Intrinsic Value?

Maravai LifeSciences: The Future Beyond Covid Vaccines

Jun 29

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de MRVI han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de MRVI han aumentado.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Maravai LifeSciences Holdings vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de MRVI con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (MRVI)n/a
Suelo de mercado 25% (US)1.5%
Techo de mercado 25% (US)4.6%
Media de la industria (Life Sciences)0.3%
Previsión de analistas en 3 años (MRVI)0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de MRVI en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de MRVI en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.


Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de MRVI para determinar si sus pagos de dividendos están cubiertos por los beneficios.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que MRVI no ha comunicado ningún pago.


Discover strong dividend paying companies